GLP-1 drugs are being explored as potential treatments for a range of conditions. View on euronews ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Ozempic is primarily used for managing type 2 ... though it’s not a weight loss medication. Starting dose: 0.25 mg weekly for 4 weeks. Gradually increased to a maximum dose of 2.0 mg weekly.

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...

The Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, ...

Its highly-anticipated iPhone model will be 2 millimeters thinner than existing models — a decrease of roughly 25%, per Bloomberg, which cheekily likened devices of the skinny phone trend to Ben ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

“The type of food GLP-1 users want changes; their tastebuds change,” says New York-based physician Dr Alexandra Sowa, author of The Ozempic Revolution (HarperCollins, £25). “People crave ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.